Core Viewpoint - The stock of Baiaosaitu-B (02315) rose over 6% following the announcement of the first patient dosing in the clinical trial of IDE034, triggering a $5 million milestone payment from IDEAYA to Baiaosaitu [1] Group 1: Company Developments - Baiaosaitu-B's stock increased by 6.49%, reaching HKD 53.35, with a trading volume of HKD 28.27 million [1] - IDEAYA announced the completion of the first patient enrollment in the Phase I dose escalation/expansion clinical trial for IDE034, a dual-target B7H3/PTK7 TOP1 antibody-drug conjugate (ADC) [1] - The first patient dosing of IDE034 will trigger a $5 million milestone payment from IDEAYA to Baiaosaitu as per their licensing agreement [1] Group 2: Product and Regulatory Milestones - IDE034 is a potentially first-in-class dual-target B7H3/PTK7 TOP1 ADC, developed by Baiaosaitu and licensed to IDEAYA in July 2024 [1] - The project received FDA approval for clinical trials in December of the previous year, marking a significant milestone in the collaboration between Baiaosaitu and IDEAYA [1] - The IND approval signifies an important step for the advancement of IDE034's clinical development, showcasing Baiaosaitu's technical strength in the field of dual antibody ADC discovery and development [1]
港股异动 午前涨超6% IDE034首例患者给药 触发500万美元里程碑款项